Quoin Pharmaceuticals Signs Research Agreement With University College Cork Encompassing The Development Of Topical Formulations Of Rapamycin
Portfolio Pulse from Benzinga Newsdesk
Quoin Pharmaceuticals has signed a research agreement with University College Cork to develop topical formulations of Rapamycin.
June 12, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quoin Pharmaceuticals has entered into a research agreement with University College Cork to develop topical formulations of Rapamycin, which could enhance their product pipeline and market position.
The partnership with a reputable academic institution like University College Cork to develop new formulations of Rapamycin could lead to innovative products, potentially boosting Quoin Pharmaceuticals' market position and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100